Physician profile
Ryan Karmouta
NPI 1316441066
$6,208.39
in general payments reported to CMS, 2019-2025
24 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $418 · 2023: $1,658 · 2024: $2,457 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,610 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,610.07 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $808.06 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $807.38 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $728.23 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $473.43 | 2022-2025 | |
| Lilly USA, LLC | $429.73 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $390.35 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $386.43 | 2022-2025 | |
| Genzyme Corporation | $339.75 | 2022-2025 | |
| Dermavant Sciences, INC. | $322.48 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $289.65 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $249.08 | 2024-2025 | Zoryve |
| Incyte Corporation | $201.71 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $162.26 | 2024-2025 | |
| Strata Skin Sciences, INC. | $137.71 | 2022-2025 | Xtrac |
| Ucb, INC. | $135.24 | 2024-2025 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Amgen INC. | $57.18 | 2023 | Otezla |
| Organon LLC | $51.81 | 2025 | Vtama |
| Botanix Sb INC | $50.97 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $21.62 | 2025 | Ycanth |
| Sandoz INC. | $20.12 | 2025 | Hyrimoz |
| Celgene Corporation | $18.63 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $14.76 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Karmouta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.